Overview

Pharmacokinetic and Pharmacodynamic of Rocuronium

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.
Details
Lead Sponsor:
Pontificia Universidad Catolica de Chile
Treatments:
Bromides
Rocuronium